"If we believe in free trade, it makes no sense to give 
			long-term patent protections to pharmaceuticals. In reality, 
			prescription drugs are a social good."--Dean Baker, 
			Economist 
			"The good of the people is the greatest law."--Marcus 
			T. Cicero, Roman Orator  
			There is no doubt that the high price of drugs must be attributed 
			to the oligopolistic position of pharmaceutical corporations and to 
			the granting of long term patent protection.  
			And the poor nations are aggrieved for the reason that the richer 
			countries are the beneficiaries of the patent protection, that the 
			drug prices are relatively much higher with respect to peoples 
			income, and that the profit motive of the corporations skews their 
			research towards the figuring out how to help rich people be more 
			sexually potent, or look young forever, or have tall children.  
			This is not the whole story as the US corporations have their 
			research subsidized by more than 50% by the National Institutes of 
			Health, universities, charities and other agencies. And more than 
			two third of these researches are directed not toward breakthroughs 
			to better our lives but toward finding ways around the lucrative 
			patents of competitors so as to produce alternative drugs and enjoy 
			a slice of the market. Additional expenses go into direct marketing 
			costs at the tune of 55 percent of the companies' research, and on 
			top of these wastes economist Dean Baker has observed that 
			"monopoly profits are an enormous incentive for companies to 
			overstate the benefits and understate the risks of the newest wonder 
			drugs." The defence of the patent protections are further 
			maintained in Washington where the pharmaceutical industry has the 
			best oiled lobby and many friends, including Defense Secretary 
			Donald Rumsfeld who is former chief executive of the drug maker G. 
			D. Searle.  
			And by the way, both Health Canada and the US Department of 
			Health and Services threatened to issue a compulsory license for the 
			production of generic Cipro unless the patent holder Bayer would cut 
			the price for the drug, and as a consequence I don't see why 
			developing countries couldn't have done the same as they experienced 
			public health emergencies such as the AIDS epidemic in Sub-Saharan 
			Africa.  
			So, this protection of intellectual rights for pharmaceutical 
			corporations has little to do with helping the well being of people 
			and the recouping of research cost, it is again the same story of 
			having corporations and politicians helping themselves at the 
			expense of people at large.  
			References 
			Patent Medicine, by Dean Baker, January 29, 2001, The American 
			Prospect http://www.americanprospect.com/print/V12/2/baker-d.html
			 
			The Price Isn't Right, by Merrill Goozner, September 11, 2000, 
			The American Prospect http://www.americanprospect.com/print/V11/20/goozner-m.html
			 
			A Muscular Lobby Tries to Shape Nation's Bioterror Plan, by 
			Leslie Wayne and Melody Petersen, New York Times November 4, 2001 
			http://www.nytimes.com/2001/11/04/business/04PHAR.html  
			Fourth Ministerial Conference in Doha Developing countries seek 
			amendment to WTO drug patent guidelines, by Amol Sharma, Earth Times 
			News Service, November 3, 2001 http://www.earthtimes.org/nov/worldtradeorgfourthnov3_01.htm
			 
			An overview of the AIDS epidemic. United Nations Special Session 
			on HIV/AIDS, 25-27 June 2001 http://www.unaids.org/fact_sheets/ungass/html/FSoverview_en.htm   |